Panobinostat

FARYDAK®

Overview

Panobinostat is a cancer medicine that interferes with the growth and spread of cancer cells in the body. It has been approved to be used in combination with bortezomib and dexamethasone to treat people with multiple myeloma who have received at least two other standard treatments (including bortezomib and an immunomodulating agent).

SparkCures ID 30
Developed By Novartis
Brand Name Farydak®
Generic Name Panobinostat
Additional Names LBH-589
Treatment Classifications

Clinical Trials

All Clinical Trials

View all active clinical trials around the US.

Early Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received one to two prior lines of therapy.

Late Relapse Multiple Myeloma

The following is a listing of clinical trials for patients with multiple myeloma who have received three or more prior lines of therapy.

Smoldering Myeloma
Monoclonal Gammopathy of Undetermined Significance (MGUS)

Resources

There are no resources, links or videos to display for this treatment.